Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Accumulated Expenses (2019 - 2026)

Kymera Therapeutics has reported Other Accumulated Expenses over the past 8 years, most recently at $409000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 97.09% to $409000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $409000.0 through Mar 2026, down 97.09% year-over-year, with the annual reading at $21.4 million for FY2025, 19.94% up from the prior year.
  • Other Accumulated Expenses was $409000.0 for Q1 2026 at Kymera Therapeutics, down from $21.4 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $21.4 million in Q4 2025 and troughed at $178000.0 in Q2 2024.
  • The 5-year median for Other Accumulated Expenses is $1.5 million (2023), against an average of $6.5 million.
  • Year-over-year, Other Accumulated Expenses tumbled 98.0% in 2022 and then surged 9265.17% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $303000.0 in 2022, then soared by 4883.17% to $15.1 million in 2023, then rose by 17.9% to $17.8 million in 2024, then rose by 19.94% to $21.4 million in 2025, then plummeted by 98.08% to $409000.0 in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Other Accumulated Expenses are $409000.0 (Q1 2026), $21.4 million (Q4 2025), and $14.6 million (Q3 2025).